SEC Filing Summary for Robert Azelby

Robert Azelby, a director at ADC Therapeutics SA, acquired 45,000 shares of Common Stock through an annual grant of restricted stock units (RSUs) on June 1, 2026. These RSUs vest on the earlier of one year from the grant date or the 2027 Annual Meeting of Shareholders, contingent upon continued service. On June 3, 2026, Azelby disposed of 12,600 shares of Common Stock. This disposal was to cover tax withholding obligations related to the vesting of previously granted RSUs. Following these transactions, Azelby holds 112,805 shares of Common Stock directly.